Germany

In late November – early December 2021, the application period for 2023 ICD-10-GM (German modification of ICD-10 diagnosis codes), OPS (procedure codes), and DRG changes was opened by the Federal Institute for Drugs and Medical Devices (BfArM), and the Institute for Hospital Remuneration Systems (INeK), respectively.

On November 12, 2021, the Innovation Committee at the Federal Joint Committee (G-BA) has announced the selection of thirty project ideas for Innovation Funding of the new forms of care within the framework of the two-stage application process. A total of 123 project ideas were received, and only thirty were accepted.

In late November 2021, the INeK (Institute for the Hospital Remuneration System) has published the DRG catalog (Fallpauschalen-Katalog) with the list of DRGs and add-on reimbursement categories (ZEs) for 2022. Seven new DRGs and seventeen ZE categories were added to the catalog in 2022.

In early-mid November 2021, the Federal Joint Committee (G-BA) has initiated an evaluation procedure for early benefit assessment for two new cardiovascular technologies (Revivent TC™ by BioVentrix and Trilogy™ Heart Valve System by JenaValve Technology) in heart failure, and aortic valve insufficiency and stenosis, respectively.

In late October 2021, the BfArM (Federal Institute for Drugs and Medical Devices) has published the final version of the 2022 OPS procedure coding classification. The OPS, together with the ICD-10-GM (International Statistical Classification of Diseases and Related Health Problems, 10th revision, German Modification), forms the basis for the reimbursement systems in outpatient and inpatient care.

In early October 2021, three more health apps were introduced in the Directory of digital health applications (DiGAs) at the Federal Office for Drugs and Medical Devices (BfArM) and thus became reimbursable. These apps can be prescribed by physicians and psychotherapists and will be reimbursed by health insurers. In total, 23 health apps are now available at the DiGA Directory.

On September 16, 2021, the Federal Joint Committee (G-BA) has decided that it would not evaluate the proton therapy in a number of indications, including esophageal cancer and inoperable hepatocellular carcinoma (HCC).

The revised EBM (German Uniform Evaluation Standard) catalog came into force on October 1, 2021. The most significant changes concern mainly IVD tests: extension of the newborn screening, the introduction of microsatellite instability testing, amendments of Oncotype DX® test reimbursement, the introduction of screening for hepatitis B and C as part of health check-up, as well as changes in reimbursement of radiation therapy services.

On September 15, 2021, the Evaluation Committee (Bewertungsausschuss) has decided to introduce in the EBM (German Uniform Evaluation Standard) the new code for Oncotype DX® testing. This change is introduced in the updated EBM version, which was published on October 1, 2021.

In late August 2021, the Innovation Committee at the Federal Joint Committee (G-BA) has announced funding of 52 innovative projects on health care research from the G-BA Innovation Fund.

On August 23, 2021, the Institute for Quality and Efficiency in Health Care (IQWiG) has presented an updated draft version (6.1) of its general methods. The interested parties can submit written comments until the deadline of October 4, 2021.

On September 1, 2021, the Institute for Hospital Remuneration Systems (INeK) announced the start of the application process according to §6 (2) KHEntgG (New Examination and Treatment Methods, NUB) for 2022.